• Journal Article

Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the UK: results from a discrete-choice experiment

Citation

Gonzalez, J., Johnson, F. R., McAteer, H., Posner, J., & Mughal, F. (2016). Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the UK: results from a discrete-choice experiment. British Journal of Dermatology, Advance Online Publication. DOI: 10.1111/bjd.14798

Abstract

Background Plaque psoriasis can have a significant negative effect on patient quality of life, and treatments can result in serious toxicities. Although there have been several studies of patients’ and physicians’ relative preferences for the benefits and risks of psoriasis treatments, it is unclear how and whether patients’ and physicians’ preferences for the outcomes of psoriasis treatments differ. Objectives The objective of this study is to quantify patient and dermatologist preferences for improvements in psoriasis symptoms as well as for increases in the risk of treatment-related serious adverse events. Methods Members of the United Kingdom (UK) Psoriasis Association and UK dermatologists with experience prescribing biologics completed a web-enabled discrete-choice experiment survey in which they evaluated efficacy and safety features of biological treatments for psoriasis. Choices between hypothetical treatment options were used to estimate preference weights indicating respondents’ relative trade-off preferences among treatment outcomes. These outcomes included improvements in the severity and coverage of psoriatic plaques and treatment-related risks of tuberculosis, serious infections, and lymphoma. Preference estimates were used to derive the maximum level of side-effect risks that respondents would accept for improvements in psoriasis symptoms. Results Results showed that respondents’ tolerance for side-effect risks varied with side-effect severity and location of plaques, and that risk tolerance for serious side effects was greater for patients than for dermatologists. Conclusions Estimates of patients’ risk tolerance for serious side effects indicate that patients valued psoriasis-symptom control highly and suggest that psoriasis symptoms have a significant effect on patients’ quality of life. In light of research showing increased treatment satisfaction and improved treatment adherence among patients who receive therapies that are consistent with their preferences, our findings suggest that greater communication between dermatologists and patients about risk tolerance could help improve patient care. This article is protected by copyright. All rights reserved.